PDCD1 and neoplasm: Monalizumab is a humanized anti-NKG2A antibody, which can enhance the anti-tumor ability of NK cells, and can rebuild the anti-tumor ability of CD8+ T cells when blocked with PD-1/PD-L1 axis at the same time.